Kamada Ltd. (KMDA)
USD 6.09
(3.05%)
USD 6.09
(3.05%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 144.75 Million USD | 11.92% |
| 2022 | 129.33 Million USD | 24.79% |
| 2021 | 103.64 Million USD | -22.22% |
| 2020 | 133.24 Million USD | 4.76% |
| 2019 | 127.18 Million USD | 11.11% |
| 2018 | 114.46 Million USD | 11.32% |
| 2017 | 102.82 Million USD | 32.69% |
| 2016 | 77.49 Million USD | 10.53% |
| 2015 | 70.11 Million USD | -2.52% |
| 2014 | 71.92 Million USD | 1.84% |
| 2013 | 70.62 Million USD | -2.82% |
| 2012 | 72.67 Million USD | 29.96% |
| 2011 | 55.92 Million USD | 54.16% |
| 2010 | 36.27 Million USD | 142.16% |
| 2009 | 14.97 Million USD | -1.54% |
| 2008 | 15.21 Million USD | 13.22% |
| 2007 | 13.43 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 41.87 Million USD | 11.98% |
| 2024 Q1 | 37.39 Million USD | -2.48% |
| 2023 Q4 | 38.35 Million USD | 1.1% |
| 2023 FY | 144.75 Million USD | 11.92% |
| 2023 Q2 | 37.44 Million USD | 21.92% |
| 2023 Q3 | 37.93 Million USD | 1.31% |
| 2023 Q1 | 30.71 Million USD | -32.41% |
| 2022 Q4 | 45.43 Million USD | 41.04% |
| 2022 Q3 | 32.21 Million USD | 36.57% |
| 2022 FY | 129.33 Million USD | 24.79% |
| 2022 Q1 | 28.09 Million USD | -10.73% |
| 2022 Q2 | 23.59 Million USD | -16.03% |
| 2021 Q4 | 31.46 Million USD | 36.62% |
| 2021 Q2 | 24.23 Million USD | -2.65% |
| 2021 Q3 | 23.03 Million USD | -4.97% |
| 2021 FY | 103.64 Million USD | -22.22% |
| 2021 Q1 | 24.9 Million USD | -21.06% |
| 2020 Q4 | 31.54 Million USD | -10.71% |
| 2020 Q2 | 33.08 Million USD | -0.6% |
| 2020 Q1 | 33.29 Million USD | 3.8% |
| 2020 Q3 | 35.32 Million USD | 6.76% |
| 2020 FY | 133.24 Million USD | 4.76% |
| 2019 FY | 127.18 Million USD | 11.11% |
| 2019 Q3 | 33.06 Million USD | -6.2% |
| 2019 Q4 | 32.07 Million USD | -3.01% |
| 2019 Q2 | 35.25 Million USD | 31.56% |
| 2019 Q1 | 26.79 Million USD | -44.42% |
| 2018 Q1 | 17.44 Million USD | -51.16% |
| 2018 Q4 | 48.21 Million USD | 221.94% |
| 2018 Q3 | 14.97 Million USD | -55.75% |
| 2018 FY | 114.46 Million USD | 11.32% |
| 2018 Q2 | 33.84 Million USD | 94.04% |
| 2017 Q3 | 22.91 Million USD | -29.59% |
| 2017 FY | 102.82 Million USD | 32.69% |
| 2017 Q4 | 35.71 Million USD | 55.82% |
| 2017 Q2 | 32.54 Million USD | 179.44% |
| 2017 Q1 | 11.64 Million USD | -51.98% |
| 2016 FY | 77.49 Million USD | 10.53% |
| 2016 Q1 | 14.79 Million USD | -42.8% |
| 2016 Q2 | 19.06 Million USD | 28.85% |
| 2016 Q3 | 19.37 Million USD | 1.61% |
| 2016 Q4 | 24.25 Million USD | 25.22% |
| 2015 Q2 | 19.24 Million USD | 115.52% |
| 2015 Q4 | 25.86 Million USD | 60.98% |
| 2015 Q3 | 16.06 Million USD | -16.51% |
| 2015 Q1 | 8.93 Million USD | -65.38% |
| 2015 FY | 70.11 Million USD | -2.52% |
| 2014 Q3 | 17.15 Million USD | 8.56% |
| 2014 Q1 | 13.18 Million USD | -46.03% |
| 2014 FY | 71.92 Million USD | 1.84% |
| 2014 Q2 | 15.79 Million USD | 19.79% |
| 2014 Q4 | 25.79 Million USD | 50.38% |
| 2013 Q3 | 17.48 Million USD | 8.47% |
| 2013 Q2 | 16.11 Million USD | 27.94% |
| 2013 FY | 70.62 Million USD | -2.82% |
| 2013 Q4 | 24.43 Million USD | 39.77% |
| 2013 Q1 | 12.59 Million USD | -41.8% |
| 2012 Q4 | 21.64 Million USD | 22.43% |
| 2012 FY | 72.67 Million USD | 29.96% |
| 2012 Q2 | 13.75 Million USD | 0.0% |
| 2012 Q3 | 17.67 Million USD | 28.55% |
| 2011 FY | 55.92 Million USD | 54.16% |
| 2010 FY | 36.27 Million USD | 142.16% |
| 2009 FY | 14.97 Million USD | -1.54% |
| 2008 FY | 15.21 Million USD | 13.22% |
| 2007 FY | 13.43 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bright Green Corporation | 401.49 Thousand USD | -35955.301% |
| Alpha Teknova, Inc. | 36.68 Million USD | -294.61% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 70.264% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -186.181% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 74.459% |
| Cosmos Health Inc. | 53.37 Million USD | -171.201% |
| Journey Medical Corporation | 79.18 Million USD | -82.82% |
| Embecta Corp. | 1.12 Billion USD | 87.084% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -24.434% |
| Dynavax Technologies Corporation | 232.28 Million USD | 37.68% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 68.827% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 78.554% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -500.839% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -500.839% |
| SCYNEXIS, Inc. | 140.14 Million USD | -3.295% |
| Safety Shot Inc | 202.67 Thousand USD | -71325.859% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -7406.301% |
| Procaps Group, S.A. | 409.92 Million USD | 64.686% |
| Theratechnologies Inc. | 81.76 Million USD | -77.045% |
| Harrow Health, Inc. | 130.19 Million USD | -11.188% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -1036.7% |
| Biofrontera Inc. | 34.07 Million USD | -324.874% |
| DURECT Corporation | 8.54 Million USD | -1593.481% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 76.172% |
| Cronos Group Inc. | 88.84 Million USD | -62.942% |
| OptiNose, Inc. | 70.98 Million USD | -103.923% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 67.304% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -2122.554% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 66.579% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -1081.844% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -265.991% |
| Radius Health, Inc. | 2.88 Billion USD | 94.978% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -348.048% |
| ProPhase Labs, Inc. | 44.38 Million USD | -226.151% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 85.776% |
| Procaps Group S.A. | 409.92 Million USD | 64.686% |
| Alvotech | 91.43 Million USD | -58.321% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -11018.187% |
| Viatris Inc. | 15.42 Billion USD | 99.062% |
| Rockwell Medical, Inc. | 83.61 Million USD | -73.132% |
| Aytu BioPharma, Inc. | 81 Million USD | -78.71% |
| SIGA Technologies, Inc. | 139.91 Million USD | -3.46% |
| Tilray Brands, Inc. | 788.94 Million USD | 81.652% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -12.863% |
| Shineco, Inc. | 9.8 Million USD | -1376.851% |
| PetIQ, Inc. | 1.1 Billion USD | 86.864% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -1206223.242% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 92.329% |
| Alimera Sciences, Inc. | 80.75 Million USD | -79.259% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1134.918% |
| Assertio Holdings, Inc. | 152.06 Million USD | 4.807% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2386.244% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -731.135% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -13348.357% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -417.68% |
| Hempacco Co., Inc. | 4.04 Million USD | -3478.146% |
| Talphera, Inc. | 651 Thousand USD | -22136.373% |
| Alvotech | 91.43 Million USD | -58.321% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 54.279% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 88.834% |
| Currenc Group, Inc. | 53.25 Million USD | -171.82% |
| Indivior PLC | 1.09 Billion USD | 86.756% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2694.231% |
| Flora Growth Corp. | 76.07 Million USD | -90.294% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -13348.357% |
| Evolus, Inc. | 202.08 Million USD | 28.367% |
| HUTCHMED (China) Limited | 837.99 Million USD | 82.726% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 77.536% |
| Akanda Corp. | 2.16 Million USD | -6601.634% |